Weiss Ratings Reiterates Sell (E+) Rating for 111 (NASDAQ:YI)

111 (NASDAQ:YI)‘s stock had its “sell (e+)” rating reissued by research analysts at Weiss Ratings in a research note issued to investors on Wednesday,Weiss Ratings reports.

111 Stock Performance

NASDAQ:YI opened at $8.18 on Wednesday. The firm has a 50-day simple moving average of $7.83 and a two-hundred day simple moving average of $7.57. The firm has a market cap of $70.71 million, a P/E ratio of -2.05 and a beta of 0.47. 111 has a fifty-two week low of $4.15 and a fifty-two week high of $12.90.

111 (NASDAQ:YI) last issued its quarterly earnings results on Thursday, March 20th. The company reported ($0.04) earnings per share for the quarter. The business had revenue of $527.14 million for the quarter.

Institutional Trading of 111

Hedge funds have recently added to or reduced their stakes in the business. Napean Trading & Investment Co Singapore PTE Ltd purchased a new stake in shares of 111 during the fourth quarter valued at about $245,000. JPMorgan Chase & Co. grew its stake in shares of 111 by 43,619.9% during the 4th quarter. JPMorgan Chase & Co. now owns 306,039 shares of the company’s stock worth $191,000 after purchasing an additional 305,339 shares during the period. FIL Ltd acquired a new stake in 111 in the 4th quarter valued at $450,000. Deuterium Capital Management LLC acquired a new stake in 111 in the 1st quarter valued at $81,000. Finally, Connor Clark & Lunn Investment Management Ltd. purchased a new position in 111 in the 1st quarter valued at $92,000. 21.32% of the stock is owned by hedge funds and other institutional investors.

About 111

111, Inc engages in the provision of pharmaceutical products and medical services through online retail pharmacy and indirectly through offline pharmacy network. It operates through the B2C and B2B segments. The B2C segment engages in the sale of pharmaceutical and other health and wellness products directly to consumers through 1 Drugstore and its offline pharmacies.